Endocrinology, Vol 123, 1652-1659, Copyright © 1988 by Endocrine Society

ARTICLES

Human recombinant mullerian inhibiting substance inhibition of rat oocyte meiosis is reversed by epidermal growth factor in vitro

S Ueno, TF Manganaro and PK Donahoe
Pediatric Surgical Research Laboratory, Massachusetts General Hospital, Boston 02114.

Mullerian inhibiting substance (MIS), a glycoprotein responsible for the regression of Mullerian duct in the male mammalian embryo, was recently localized not only in the fetal and newborn testis, but also in the older ovary throughout reproductive life. Bovine MIS purified from newborn testicular tissue inhibited spontaneous oocyte meiosis in vitro in the rat. These studies show that partially purified recombinant MIS produced from a human MIS genomic construct caused inhibition of oocyte meiosis, but when purified to homogeneity, the effect was lost. Addition of low concentrations of the detergent Nonidet P-40, used to maintain stability in the purified bovine preparations, however, restored the MIS inhibitory effect to the human preparation, which could, in turn, be blocked by a polyclonal antibody raised to human recombinant MIS; Nonidet P-40 itself caused no inhibition. Since we have shown that epidermal growth factor (EGF) and MIS are antagonistic in a number of other systems, we tested the effect of EGF on the ability of MIS to inhibit oocyte meiosis. EGF added to the medium at a dose that caused no effect on oocytes (25 ng/ml) blocked the MIS inhibitory action on spontaneous rat oocyte meiosis, while EGF had no effect on a known oocyte meiosis inhibitor, 3-isobutyl- 1-methylxanthine. These data indicate that human recombinant MIS can inhibit oocyte meiosis in the ovary and that its regulatory effect can be modulated by EGF, which appears to be an antagonist of MIS.

This article has been cited by other articles:

				S J Martins da Silva, J O Gardner, J E Taylor, A Springbett, P A De Sousa, and R A Anderson Brain-derived neurotrophic factor promotes bovine oocyte cytoplasmic competence for embryo development Reproduction, April 1, 2005; 129(4): 423 - 434. [Abstract] [Full Text] [PDF]

				A. E. Stephen, L. A. Pearsall, B. P. Christian, P. K. Donahoe, J. P. Vacanti, and D. T. MacLaughlin Highly Purified Mullerian Inhibiting Substance Inhibits Human Ovarian Cancer in Vivo Clin. Cancer Res., August 1, 2002; 8(8): 2640 - 2646. [Abstract] [Full Text] [PDF]

				J. Teixeira, S. Maheswaran, and P. K. Donahoe Mullerian Inhibiting Substance: An Instructive Developmental Hormone with Diagnostic and Possible Therapeutic Applications Endocr. Rev., October 1, 2001; 22(5): 657 - 674. [Abstract] [Full Text] [PDF]

				A. M. Trbovich, P. M. Sluss, V. M. Laurich, F. H. O'Neill, D. T. MacLaughlin, P. K. Donahoe, and J. Teixeira Mullerian Inhibiting Substance lowers testosterone in luteinizing hormone-stimulated rodents PNAS, March 1, 2001; (2001) 51632298. [Abstract] [Full Text]

				A. E. Stephen, P. T. Masiakos, D. L. Segev, J. P. Vacanti, P. K. Donahoe, and D. T. MacLaughlin Tissue-engineered cells producing complex recombinant proteins inhibit ovarian cancer in vivo PNAS, February 22, 2001; (2001) 51625998. [Abstract] [Full Text]

				N. Morikawa, T. R. Clarke, C. D. Novina, K. Watanabe, C. Haqq, M. Weiss, A. L. Roy, and P. K. Donahoe Human Mullerian-Inhibiting Substance Promoter Contains a Functional TFII-I-Binding Initiator Biol Reprod, October 1, 2000; 63(4): 1075 - 1083. [Abstract] [Full Text]

				P. T. Masiakos, D. T. MacLaughlin, S. Maheswaran, J. Teixeira, A. F. Fuller Jr., P. C. Shah, D. J. Kehas, M. K. Kenneally, D. M. Dombkowski, T. U. Ha, et al. Human Ovarian Cancer, Cell Lines, and Primary Ascites Cells Express the Human Mullerian Inhibiting Substance (MIS) Type II Receptor, Bind, and Are Responsive to MIS Clin. Cancer Res., November 1, 1999; 5(11): 3488 - 3499. [Abstract] [Full Text] [PDF]

				J. Teixeira, E. Fynn-Thompson, A. H. Payne, and P. K. Donahoe Mullerian-Inhibiting Substance Regulates Androgen Synthesis at the Transcriptional Level Endocrinology, October 1, 1999; 140(10): 4732 - 4738. [Abstract] [Full Text]

				C. M. HAQQ and P. K. DONAHOE Regulation of Sexual Dimorphism in Mammals Physiol Rev, January 1, 1998; 78(1): 1 - 33. [Abstract] [Full Text] [PDF]

				D. L. Segev, T. U. Ha, T. T. Tran, M. Kenneally, P. Harkin, M. Jung, D. T. MacLaughlin, P. K. Donahoe, and S. Maheswaran Mullerian Inhibiting Substance Inhibits Breast Cancer Cell Growth through an NFkappa B-mediated Pathway J. Biol. Chem., September 8, 2000; 275(37): 28371 - 28379. [Abstract] [Full Text] [PDF]

				T. U. Ha, D. L. Segev, D. Barbie, P. T. Masiakos, T. T. Tran, D. Dombkowski, M. Glander, T. R. Clarke, H. K. Lorenzo, P. K. Donahoe, et al. Mullerian Inhibiting Substance Inhibits Ovarian Cell Growth through an Rb-independent Mechanism J. Biol. Chem., November 17, 2000; 275(47): 37101 - 37109. [Abstract] [Full Text] [PDF]

				A. E. Stephen, P. T. Masiakos, D. L. Segev, J. P. Vacanti, P. K. Donahoe, and D. T. MacLaughlin Tissue-engineered cells producing complex recombinant proteins inhibit ovarian cancer in vivo PNAS, March 13, 2001; 98(6): 3214 - 3219. [Abstract] [Full Text] [PDF]

				A. M. Trbovich, P. M. Sluss, V. M. Laurich, F. H. O'Neill, D. T. MacLaughlin, P. K. Donahoe, and J. Teixeira Mullerian Inhibiting Substance lowers testosterone in luteinizing hormone-stimulated rodents PNAS, March 13, 2001; 98(6): 3393 - 3397. [Abstract] [Full Text] [PDF]